On March 4, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that it will present its Cchek artificial intelligence (AI) based liquid biopsy for the early detection of cancer technology and its most recent data in an oral presentation at the 26th International Molecular Medicine Tri-Conference (Press release, Anixa Biosciences, MAR 4, 2019, View Source [SID1234533952]). Cchek utilizes flow cytometry of white blood cells and AI to identify tumor-bearing patients. Dr. Kumar, President and CEO of Anixa, will make his presentation at 12:15 pm on March 14, 2019. The symposium in which the presentation will be made is focused on early cancer detection (View Source).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Molecular Medicine Tri-Conference is one of the largest commercial conferences addressing the latest advances in biotechnology, diagnostics and life sciences," said Dr. Kumar. "I am pleased to be telling people about our technology, how it works, and the latest performance data on the detection of prostate cancer, breast cancer and several other types of cancer. This is a timely conference as we approach the commercial launch of our Cchek Prostate Cancer Confirmation test later this year."